Eleanor M. Scott, Egon J. Jacobus, Brian Lyons, Sally Frost, Joshua D. Freedman, Arthur Dyer, Hena Khalique, William K. Taverner, Alison Carr, Brian R. Champion, Kerry D. Fisher, Len W. Seymour* and Margaret R. Duffy
Journal for ImmunoTherapy of Cancer (2019) 7:320
Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, Miller P, Kanellakis N, Ashfield R, Fisher KD, Duffy MR, Seymour LW. EMBO Mol Med 9:1067-1087 (2017)
JD Freedman, MR Duffy, J Lei-Rossmann, A Muntzer, EM Scott, J Hagel, L Campo, RJ Bryant, C Verrill, A Lambert, P Miller, BR Champion, LW Seymour and KD Fisher. Cancer Res 2018, 1–14, AACR.
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Illingworth S, Di Y, Bauzon M, Lei J, Duffy MR, Alvis S, Champion B, Lieber A, Hermiston T, Seymour LW, Fisher K. Mol Ther Oncolytics. 2017;5:62-74
Marino N, Illingworth S, Kodialbail P, Patel A, Calderon H, Lear R, Fisher KD, Champion BR, Brown ACN. PLoS One 2017;12(5):e0177810.
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion*, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle and Emiliano Calvo. Journal for ImmunoTherapy of Cancer (2019) 7:20
Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K.
Journal for ImmunoTherapy of Cancer2017 5:71
A multicenter, open-label, first in human study of a vector expressing and agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors.